1613169-00-8Relevant articles and documents
Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells
Cherian, Joseph,Nacro, Kassoum,Poh, Zhi Ying,Guo, Samantha,Jeyaraj, Duraiswamy A.,Wong, Yun Xuan,Ho, Melvyn,Yang, Hai Yan,Joy, Joma Kanikadu,Kwek, Zekui Perlyn,Liu, Boping,Wee, John Liang Kuan,Ong, Esther Hq,Choong, Meng Ling,Poulsen, Anders,Lee, May Ann,Pendharkar, Vishal,Ding, Li Jun,Manoharan, Vithya,Chew, Yun Shan,Sangthongpitag, Kanda,Lim, Sharon,Ong, S. Tiong,Hill, Jeffrey,Keller, Thomas H.
, p. 3063 - 3078 (2016/05/19)
Clinically used BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia do not eliminate leukemic stem cells (LSC). It has been shown that MNK1 and 2 inhibitors prevent phosphorylation of eIF4E and eliminate the self-renewal capacity of LSCs. Herein, we describe the identification of novel dual MNK1 and 2 and BCR-ABL1 inhibitors, starting from the known kinase inhibitor 2. Initial structure-activity relationship studies resulted in compound 27 with loss of BCR-ABL1 inhibition. Further modification led to orally bioavailable dual MNK1 and 2 and BCR-ABL1 inhibitors 53 and 54, which are efficacious in a mouse xenograft model and also reduce the level of phosphorylated eukaryotic translation initiation factor 4E in the tumor tissues. Kinase selectivity of these compounds is also presented.
